What selectivity buys you
Selectivity is the ratio of how hard a molecule hits its intended target versus everything else. An off-target interaction can cause side effects that limit dose or stop a program. The cleaner the molecule, the wider the therapeutic index — the gap between the dose that works and the dose that harms.
Selectivity optimization is most natural to do alongside potency: you run counter-screens against the nearest relatives of your target (sister enzymes, related receptors) every cycle, and treat the selectivity ratio as just another gauge in your MPO. The earlier you watch it, the easier it is to steer.
How to build selectivity in
- Exploit a difference. Find a residue or pocket shape unique to your target and design a contact that only it can make — the surest route to selectivity.
- Use shape and rigidity. Locking the molecule into the conformation your target prefers often costs an off-target more binding energy than it costs your target.
- Track the ratio, not just the wins. A change that boosts target potency 3x but off-target potency 10x has made you *less* selective. Always read both numbers together.
Designing out safety liabilities
Two safety liabilities sink so many candidates that you screen for them routinely. The first is hERG inhibition: blocking a cardiac potassium channel that can cause dangerous arrhythmia. hERG loves basic, lipophilic molecules, so the fixes are familiar — lower lipophilicity, reduce the basicity of an amine, or add polarity near the offending group.
The second is the reactive metabolite: when metabolism turns part of the molecule into a chemically reactive species that can bind proteins and trigger idiosyncratic toxicity. These often come from known structural alerts — anilines, thiophenes, certain phenols. The defense is to recognize the alert, then either remove it, block its metabolism, or redesign that region with a safer surrogate.